Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind randomized placebo-controlled 4-arm study of ponsegromab in heart failure
2022-001809-50Phase 2Active
- Sponsor
- Pfizer
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ponsegromab in heart failure (HF) (4 arms), sponsored by Pfizer. Primary endpoint: Change from baseline in KCCQ-23 Clinical Summary Score (CSS) at Week 22. Started Oct 2022; status: active.
02
Drugs
ponsegromab
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2022-001809-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001809-50.